Skip to main content
Clinical Trials/NCT06354491
NCT06354491
Active, Not Recruiting
N/A

An Imaging-based Quantitative Biomarker Assay for Non-alcoholic Fatty Liver Disease (NAFLD) in Children: a Feasibility Study

University of Wisconsin, Madison1 site in 1 country24 target enrollmentApril 1, 2024
ConditionsNAFLDNASH

Overview

Phase
N/A
Intervention
Not specified
Conditions
NAFLD
Sponsor
University of Wisconsin, Madison
Enrollment
24
Locations
1
Primary Endpoint
Feasibility Measured by the Number of Participants Who Successfully Complete the Interventions
Status
Active, Not Recruiting
Last Updated
4 months ago

Overview

Brief Summary

This study will validate recently developed Magnetic Resonance Imaging (MRI) and Ultrasound (US) based methods for liver fat quantification in children with obesity and healthy range of body mass index (BMI).

Detailed Description

The severity of the obesity epidemic in the U.S., particularly in Wisconsin, is alarming, with overall overweight or obesity rates of 35% in children. \[Fryar 2020,\] Obesity is a major risk factor for several comorbidities, one of the most common being non-alcoholic fatty liver disease (NAFLD, also denoted steatotic liver disease). The inflammatory state known as non-alcoholic steatohepatitis (NASH) may lead to fibrosis and, if left untreated, can lead to cirrhosis, liver failure, and cancer. For these reasons, there is enormous interest in effective interventions for weight loss and reversing NAFLD. A central challenge in the development of new interventions is the need for accurate and precise biomarkers to evaluate hepatic steatosis in children. This pilot study focuses on demonstrating the feasibility of MRI and US based liver fat quantification in children and addresses technical challenges that may limit the performance of the proposed techniques in the population of interest through the following aims: * Aim 1: Determine the bias and precision (repeatability) of emerging free-breathing MRI-based liver fat quantification in children with obesity and controls using current breath-held methods as a reference. * Aim 2: Determine the precision (repeatability and reproducibility) of US-based biomarkers of liver steatosis with a focus on the impact of body wall thickness on the precision of the biomarkers.

Registry
clinicaltrials.gov
Start Date
April 1, 2024
End Date
July 1, 2028
Last Updated
4 months ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Age: 10 - 14years old
  • BMI: Case subjects: BMI\>95th percentile for age and sex Healthy BMI volunteers: 5th ≤ BMI \< 85th percentile for age and sex

Exclusion Criteria

  • Children with contraindications to MRI.
  • Children who did not fast (verbally confirmed by children or guardian)

Outcomes

Primary Outcomes

Feasibility Measured by the Number of Participants Who Successfully Complete the Interventions

Time Frame: through study enrollment (up to approximately 14 months)

Demonstrate the feasibility of MRI- and US-based liver fat quantification in children and address technical challenges that may limit the performance of the proposed techniques in the population of interest.

Secondary Outcomes

  • MRI: Bias reported as difference in mean error in Percent Liver Fat measured from free-breathing MRI method and reference breath-held MRI method(Research visit 1 (up to 14 months))
  • MRI: Precision measured by Test-Retest of Percent Liver Fat(Research visit 1 (up to 14 months))
  • Quantitative US: Repeatability of US Measurements (same sonographer) - Attenuation Coefficient (dB/cm-MHz)(Research visit 1 (up to 14 months))
  • Quantitative US: Repeatability of US Measurements (same sonographer) - Backscatter Coefficient (1/cm*sr)(Research visit 1 (up to 14 months))
  • Quantitative US: Reproducibility of US Measurements (different sonographers) - Attenuation Coefficient (dB/cm-MHz)(Research visit 1 (up to 14 months))
  • Quantitative US: Reproducibility of US Measurements (different sonographers) - Backscatter Coefficient (1/cm*sr)(Research visit 1 (up to 14 months))

Study Sites (1)

Loading locations...

Similar Trials